PSI-7977

• CAT Number: A000754
• CAS Number: 1190307-88-0
• Molecular Formula: C₂₂H₂₉FN₃O₉P
• Molecular Weight: 529.45
• Purity: 98%
• Target: NS5b
• Solubility: Soluble in DMSO > 10 mM
• Appearance: Solid
• Storage: Dry, dark and at 2 - 8 °C for six months or -20°C for two years.
• IUPAC Name: propan-2-yl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
• InChI: InChI=1S/C22H29FN3O9P/c1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t14-,16+,18+,20+,22+,36-/m0/s1
• InChIKey: TTZHDVOVKQGIBA-IQWMDFIBSA-N
• SMILES: C[C@@H](C(=O)OC(C)C)N[P@](=O)(OC[C@@H]1[C@H]([C@@]([C@@H](O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3

Sofosbuvir（Cat No.:A000754）, also known as PSI-7977 and GS7977 (brand names Sovaldi and Virunon), is a drug used for hepatitis C virus (HCV) infection, with a high cure rate. It inhibits the RNA polymerase that the hepatitis C virus uses to replicate its RNA. It was discovered at Pharmasset and developed by Gilead Sciences. Sofosbuvir is a component of the first all-oral, interferon-free regimen approved for treating chronic Hepatitis C. In 2013, the FDA approved sofosbuvir in combination with ribavirin (RBV) for oral dual therapy of HCV genotypes 2 and 3, and for triple therapy with injected pegylated interferon (pegIFN) and RBV for treatment-naive patients with HCV genotypes 1 and 4.

Reference

1: Degasperi E, Aghemo A. Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives. Hepat Med. 2014 Apr 29;6:25-33. doi: 10.2147/HMER.S44375. eCollection 2014. Review. PubMed PMID: 24822024; PubMed Central PMCID: PMC4010630.2: Rose L, Bias TE, Mathias CB, Trooskin SB, Fong JJ. Sofosbuvir: A Nucleotide NS5B Inhibitor for the Treatment of Chronic Hepatitis C Infection. Ann Pharmacother. 2014 May 8;48(8):1019-1029. [Epub ahead of print] Review. PubMed PMID: 24811396.3: Stedman C. Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential. Therap Adv Gastroenterol. 2014 May;7(3):131-40. doi: 10.1177/1756283X13515825. Review. PubMed PMID: 24790644; PubMed Central PMCID: PMC3968818.4: Gaetano JN. Benefit-risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir. Drug Healthc Patient Saf. 2014 Mar 31;6:37-45. doi: 10.2147/DHPS.S43304. eCollection 2014. Review. PubMed PMID: 24729731; PubMed Central PMCID: PMC3976205.5: Sofosbuvir (Sovaldi) for chronic hepatitis C. Med Lett Drugs Ther. 2014 Jan 20;56(1434):5-6. Review. PubMed PMID: 24457562.6: Asselah T, Marcellin P. Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir. Liver Int. 2014 Feb;34 Suppl 1:60-8. doi: 10.1111/liv.12424. Review. PubMed PMID: 24373080.7: Asselah T. Sofosbuvir for the treatment of hepatitis C virus. Expert Opin Pharmacother. 2014 Jan;15(1):121-30. doi: 10.1517/14656566.2014.857656. Epub 2013 Nov 30. Review. PubMed PMID: 24289735.8: Mariño Z, van Bömmel F, Forns X, Berg T. New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C. Gut. 2014 Feb;63(2):207-15. doi: 10.1136/gutjnl-2013-305771. Epub 2013 Nov 19. Review. PubMed PMID: 24253934.9: Rodríguez-Torres M. Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection. Expert Rev Anti Infect Ther. 2013 Dec;11(12):1269-79. doi: 10.1586/14787210.2013.855126. Review. PubMed PMID: 24215243.10: Gentile I, Borgia F, Buonomo AR, Castaldo G, Borgia G. A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir. Curr Med Chem. 2013;20(30):3733-42. Review. PubMed PMID: 23848533.